Senior Scientist, Immunology, In Vivo Pharmacology at Bristol-Myers Squibb

Winter Garden, Florida, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Expertise in conducting in vivo research in the field of autoimmune diseases
Ability to interact seamlessly with scientists and functional groups within drug discovery teams
Experience in formulating and implementing in vivo strategies for drug discovery programs
Knowledge in identification and validation of novel disease and target-specific biomarkers
Capability to develop new pharmacodynamic and disease models for autoimmune indications
Proficiency in preparing, reviewing, and delivering scientific presentations to internal and external stakeholders
Experience interacting with senior management and key opinion leaders

Responsibilities

Develop therapeutic hypotheses for autoimmune diseases based on literature discoveries, in vitro experimental data, in vivo animal modeling, immunological evolution, genetics, clinical data, and technological advances
Collaborate alongside a cross-functional team to discover new targets, derive new biological mechanistic insights, and support in vivo pharmacology needs for programs as they move through clinical development
Identify and implement appropriate PK/PD and disease models to support clinical candidate selection, human dose projection, biomarker identification, and life cycle management
Contribute to portfolio strategy discussions and foster external collaborations to advance program objectives
Communicate scientific findings effectively across multidisciplinary teams

Skills

Immunology

In Vivo Pharmacology

Small Molecule Chemistry

Protein Biotherapeutics

Cell Therapy

Protein Degradation

Nucleic Acids

Oncology

Hematology

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free